Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

InMed Pharmaceuticals (INM) Restructuring Costs: 2022-2024

Historic Restructuring Costs for InMed Pharmaceuticals (INM) over the last 1 years, with Jun 2024 value amounting to $104,969.

  • InMed Pharmaceuticals' Restructuring Costs rose 229.36% to $104,969 in Q2 2024 from the same period last year, while for Jun 2024 it was $43,726, marking a year-over-year change of. This contributed to the annual value of $162,200 for FY2024, which is 187.55% up from last year.
  • According to the latest figures from Q2 2024, InMed Pharmaceuticals' Restructuring Costs is $104,969, which was up 974.62% from $9,768 recorded in Q1 2024.
  • In the past 5 years, InMed Pharmaceuticals' Restructuring Costs registered a high of $104,969 during Q2 2024, and its lowest value of -$81,147 during Q2 2023.
  • Moreover, its 3-year median value for Restructuring Costs was $19,289 (2023), whereas its average is $22,873.
  • Its Restructuring Costs has fluctuated over the past 5 years, first slumped by 84.42% in 2023, then skyrocketed by 229.36% in 2024.
  • Quarterly analysis of 3 years shows InMed Pharmaceuticals' Restructuring Costs stood at $65,072 in 2022, then crashed by 84.42% to $10,136 in 2023, then surged by 229.36% to $104,969 in 2024.
  • Its Restructuring Costs stands at $104,969 for Q2 2024, versus $9,768 for Q1 2024 and $10,136 for Q4 2023.